OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma TrialNewsfile Corp · Oct 6, 2026
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)Newsfile Corp · Sep 24, 2026
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma ProgramNewsfile Corp · Sep 17, 2026
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma TrialNewsfile Corp · Sep 8, 2026
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference AttendanceNewsfile Corp · Sep 2, 2026
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic OsteosarcomaNewsfile Corp · Aug 13, 2026Ostin Technology Group Co., Ltd., a company based in China, specializes in the creation and production of sophisticated thin-film transistor liquid crystal display (TFT-LCD) modules, along with essential polarizers. Its extensive product portfolio encompasses comprehensive TFT-LCD solutions, covering critical components such as drive ICs, TCON boards, and power supplies. Additionally, Ostin manufactures advanced backlight systems, specialized display modules, liquid crystal display units, interactive touch panel modules, and intelligent display terminals.